A r t i c l e s Our understanding of the innate immune system's role in homeostasis and disease has considerably expanded over the last decades. The cellular arm, in particular monocytes and their lineage-descendant macrophages, participate critically in inflammatory activity in major diseases, such as atherosclerosis and cancer. The production, recruitment and differentiation of monocytes, their subsets and their progeny have been studied in detail [1] [2] [3] . This knowledge has not yet been translated into effective clinical therapies, however, mainly because innate immune cells have a multitude of protective functions, many of which are too important for survival to compromise. A possible solution to this problem is a therapy that 'surgically' and temporarily targets cellular subsets that possess disease activity while leaving other classes of cells undisturbed, so the latter can maintain homeostasis, foster healing, resolve inflammation and keep up defenses against infection. Although such therapeutic precision has remained elusive, the emerging differential roles of monocyte and macrophage subsets make this goal more attainable.
Inflammatory monocytes (Ly-6C high in the mouse, CD14 + CD16 − in human) 3 give rise to classical macrophages and promote inflammatory disease activity. Although they are essential early responders, their excessive or prolonged recruitment hinders resolution of inflammation and propagates disease progression. The recruitment of inflammatory monocytes depends on the chemokine/chemokine-receptor pair MCP-1/CCR2, distinct from the noninflammatory monocyte subset (Ly-6C low in the mouse) that depends on fractalkine/CX3CR1 (ref. 1) . CCR2 also mediates egress of monocytes from the bone marrow 4 . Accordingly, genetic deletion of either monocyte-chemotactic protein (MCP)-1 or CCR2 results in profound reduction of inflammation in various disease models [5] [6] [7] [8] [9] [10] . Therapeutic targeting of CCR2 could thus limit harmful functions of innate immunity while leaving noninflammatory monocytes, alternatively activated macrophages, antigen-presenting cells and other tissue residents unaffected. Small molecules and neutralizing antibodies targeting the MCP-1/CCR2 axis are being investigated but often lack specificity or in vivo efficacy 1 .
Short interfering RNA (siRNA) technology shows promise to attenuate production of specific target proteins in vivo by degradation of mRNA 11, 12 . Although siRNA delivery has been the focus of considerable work, the development of formulations capable of efficacious systemic delivery to immune cells with clinically suitable delivery materials has been challenging 13 . Recent advances in siRNA design and chemistry now allow identification of specific, highly potent sequences with nuclease stability and reduced immunostimulation 14 , which we here combine with biocompatible nanoparticle delivery vehicles 15 .
We hypothesized that monocyte-targeting siRNA nanomaterials could silence CCR2 mRNA in the inflammatory monocyte subset to selectively inhibit migration (and consequently adverse function) of therapeutic sirNA silencing in inflammatory monocytes in mice Florian Leuschner 1, 11 Excessive and prolonged activity of inflammatory monocytes is a hallmark of many diseases with an inflammatory component. In such conditions, precise targeting of these cells could be therapeutically beneficial while sparing many essential functions of the innate immune system, thus limiting unwanted effects. Inflammatory monocytes-but not the noninflammatory subsetdepend on the chemokine receptor CCR2 for localization to injured tissue. Here we present an optimized lipid nanoparticle and a CCR2-silencing short interfering RNA that, when administered systemically in mice, show rapid blood clearance, accumulate in spleen and bone marrow, and localize to monocytes. Efficient degradation of CCR2 mRNA in monocytes prevents their accumulation in sites of inflammation. Specifically, the treatment attenuates their number in atherosclerotic plaques, reduces infarct size after coronary artery occlusion, prolongs normoglycemia in diabetic mice after pancreatic islet transplantation, and results in reduced tumor volumes and lower numbers of tumor-associated macrophages. 1 0 0 6 VOLUME 29 NUMBER 11 NOVEMBER 2011 nature biotechnology A r t i c l e s these cells and their progeny ( Supplementary  Fig. 1 ). Dynamic optical tomography revealed that nanoparticle-encapsulated, fluorescently tagged siRNA was rapidly redistributed from the blood pool to the spleen and bone marrow. Knockdown of CCR2 in monocytes was confirmed at the mRNA, protein and functional levels. We then tested this therapeutic approach in mouse atherosclerosis, myocardial infarction, pancreatic islet transplantation in diabetes and cancer. Treatment with clinically feasible doses of siRNA substantially reduced regional recruitment of inflammatory monocytes and attenuated disease progression in these disease models.
RESULTS

siRNA distribution
The siRNA carrier used in this study was previously identified in high-throughput in vitro screens of several hundred compounds, resulting in development of a 70-80 nm lipid-like particle with efficient cell delivery and knockdown 15 . The nanoparticle was formulated using C12-200 lipid, disteroylphosphatidyl choline, cholesterol, PEG-DMG and siRNA in a spontaneous vesicle formation procedure. The specific siRNA sequence against CCR2 (siCCR2) was identified by in vitro screening from 31 candidate sequences ( Supplementary Fig. 2 ), all chemically modified to minimize off-target effects. The best duplex with the sequence of 5′-uGcuAAAcGucucuGcAAAdTsdT-3′ (sense), 5′-UUUG cAGAGACGUUuAGcAdTsdT -3′ (anti-sense) was selected for scaleup, formulation and subsequent nanoparticle encapsulation. The final lipid:siRNA weight ratio of the nanoparticle was 7:1 with an siRNA entrapment efficiency of 95%. Figure 1 Nanoparticle-encapsulated siRNA is distributed to leukocytes. (a) Dynamic FMT-CT biodistribution imaging of siRNA shows major uptake in the spleen (dashed circle). The material is rapidly cleared from the blood pool (arrow) and excreted through the hepato-biliary route into the bowel (n = 5). (b) Immunofluorescence microscopy of the splenic red pulp shows colocalization of siRNA (red) and CD11b expression (green). Scale bar, 20 µm. Western blot analysis of Ly-6C high monocytes isolated from the spleen of mice that were either treated with siCCR2 or control. The reduced band in the siCCR2 lane confirms a lower expression of CCR2 receptor protein in splenic monocytes after intravenous treatment (experiment was done in triplicate, representative blot is cropped; the full-length blot is presented in Supplementary  Fig. 6 ). (c) FACS analysis of CCR2 protein on splenic Ly-6C high monocytes.
Representative histogram shows isotype antibody staining (black), control treatment (red) and siCCR2 treatment (blue). Bar graph of mean fluorescent intensity (MFI, y axis starts at mean fluorescence intensity of the isotype control; n = 6 per group). (d) Migration assay of sorted Ly-6C high monocytes using MCP-1 as chemoattractant. Cells were harvested from mice injected with either siCCR2 or control siRNA (n = 3 per group). Stained membranes on the left, bar graph shows enumeration of migrated cells. Mean ± s.d., *P < 0.05.
A r t i c l e s
We covalently labeled siRNA with a near-infrared fluorochrome to follow its in vivo distribution after intravenous injection with dynamic fluorescence imaging. Mice were positioned inside the fluorescence molecular tomography (FMT) scanner, and data were acquired serially for up to 24 h. siRNA concentration was determined every 5 min. Key organs were identified in co-registered X-ray computed tomography (CT). Immediately after injection, a strong fluorescence signal localized in the cardiac region, reflecting the presence of siRNA in the blood pool ( Fig. 1a , arrow). This signal was fitted over time, resulting in an siRNA blood half-life of 8.1 min (Fig. 1a) . The spleen showed the highest fluorescence per gram of tissue in the entire body, with a peak fluorescence of 391 ± 63 pmol/g tissue ( Fig. 1a , dotted circle). There was also considerable accumulation in the bone marrow and liver whereas no siRNA was detected in the lung (3 ± 4 pmol/g). Dynamic imaging showed that the siRNA was excreted by the hepato-biliary route ( Fig. 1a) . Ex vivo fluorescence reflectance imaging corroborated these findings ( Supplementary Fig. 3 ).
We next studied the intraparenchymal siRNA distribution in the spleen by fluorescence microscopy. Most of the siRNA-related fluorescence was found in cells residing in the spleen's red pulp. Spectrally resolved co-staining for CD11b colocalized this myeloid marker with siRNA in cells that formed the typical splenic reservoir monocyte clusters 16 (Fig. 1b) . We also detected uptake in Kupffer cells ( Supplementary  Fig. 4 ). Flow cytometric analysis further refined the uptake profile in cells in the bone marrow and spleen and in circulating leukocytes. Lymphocytes showed comparatively low uptake, but we detected strong signal in neutrophils, Ly-6C high and Ly-6C low monocytes, dendritic cells and macrophages (Fig. 1c) . The highest uptake was seen in splenic Ly-6C high monocytes (Fig. 1d) .
In vivo silencing in Ly-6C high monocytes Recent work described a large monocyte reservoir in the spleen that dispatches these cells to sites of local inflammation 16 . Systemic treatment with nanoparticle-encapsulated siCCR2 resulted in a significant reduction of CCR2 mRNA in Ly-6C high monocytes isolated from this population (P = 0.03, Fig. 2a) . A rapid amplification of cDNA ends (RACE) assay in splenic monocytes isolated after intravenous injection confirmed the RNA interference (RNAi) mechanism by detecting specific mRNA cleavage products (Supplementary Fig. 5 ). Cleavage of CCR2 mRNA translated into lower protein levels as seen by means of western blot analysis ( Fig. 2b  and Supplementary Fig. 6 ) and flow cytometric staining of CCR2 protein on Ly-6C high monocytes (Fig. 2c) . The capacity of Ly-6C high monocytes to migrate toward MCP-1 was drastically reduced in a migration assay (from 144 ± 31 to 2 ± 2 migrated cells, P < 0.05, Fig. 2d ).
Silencing of CCR2 reduces myocardial infarct size
Myocardial infarction (MI) elicits a strong inflammatory response and profound recruitment of innate immune cells, including inflammatory splenic reservoir monocytes 16 . The magnitude of inflammation influences infarct size and the degree of post-MI heart failure 17 A r t i c l e s underwent ischemia followed by reperfusion, we found a marked reduction in the number of monocytes and macrophages in the hearts of mice that had been injected with siCCR2 (control siRNA treatment, 16,950 ± 9,470 cells per mg infarct tissue; siCCR2 treatment, 5,158 ± 2,201; Fig. 3a,b) . The treatment lowered the number of inflammatory Ly-6C high monocytes by 71% ( Fig. 3a,b) . The infarct/area-at-risk ratio, which signifies the benefit of acute treatment after myocardial ischemia, was reduced by 34% in mice injected with siCCR2 ( Fig. 3c,d) . Splenectomy experiments confirmed that the splenic monocyte reservoir is a major target of siCCR2 treatment in acute inflammation ( Fig. 3e-g) . When treatment was started 1 h after injury, therapeutic effects were preserved ( Supplementary  Fig. 7) . A head-to-head comparison to small-molecule inhibitors of CCR2 showed superior efficacy of therapeutic silencing (Supplementary Fig. 8 ).
Silencing of CCR2 reduces inflammatory atherosclerosis
Increased invasion of Ly-6C high monocytes critically promotes progression and complication of atherosclerosis 18, 19 , whereas germline deletion of CCR2 (ref. 6) or MCP-1 (ref. 5) attenuates the disease. A 3-week siCCR2 therapy in apoE −/− mice with established atherosclerosis reduced the monocyte/macrophage number in atherosclerotic plaques by 82% (Fig. 4a,b) . Monocyte subset analysis showed a marked reduction of inflammatory Ly-6C high monocytes (7,188 ± 3,388 versus 2,281 ± 1,581). Immunohistochemical staining for CD11b indicated a 46% reduced presence of myeloid cells and a 38% reduction of lesion size in the aortic root ( Fig. 4c) .
Silencing of CCR2 prolongs islet graft survival
Pancreatic islet transplantation is a treatment option for patients with type 1 diabetes; however, allograft rejection is a major hurdle to its clinical use 20 . Ly-6C high monocytes are recruited in transplant rejection 21 , and monocytes can differentiate into highly active antigen-presenting cells 3 . Therefore, we investigated the effect of siCCR2 treatment in pancreatic islet transplantation in mice with streptozotocin-induced diabetes. Intravenous injection of nanoparticle-encapsulated siCCR2 significantly prolonged the normoglycemic period and, by association, islet graft function (P = 0.01, Fig. 5a ). Graft-dependent normoglycemia in siCCR2-treated A r t i c l e s mice was confirmed by nephrectomy, which removed the grafted islets and returned mice to a diabetic state. Histology of the grafted islets confirmed that they were rejected in control groups but not in euglycemic mice treated with siCCR2 ( Fig. 5b,c) .
Silencing of CCR2 reduces tumor-associated macrophages
The host immune system's role in cancer progression, including tumor vascularization, growth, metastasis and resistance to chemotherapy, is well established [22] [23] [24] [25] . Inflammatory monocytes contribute substantially to the host response by differentiation into tumor-associated macrophages 26 , and the number of such macrophages in patients with lymphoma inversely correlates with the length of their survival 27 . Accordingly, we investigated the effect of siCCR2 therapy in mice after implantation of lymphoma EL4 cells. Treatment was initiated when a tumor mass was palpable. In a longitudinal study, tumor growth was reduced in siCCR2treated mice (Supplementary Fig. 9 ). In a second cohort, computed tomography showed significantly reduced tumor volume 5 d after siCCR2 injections were initiated (siCCR2 treatment, 279 ± 144 mm 3 ; control siRNA treatment, 590 ± 221 mm 3 , P = 0.009; Fig. 6a ). Flow cytometric analysis of tumors showed a 54% reduction of tumor-associated macrophages in mice treated with siCCR2 ( Fig. 6b) . Histological analysis confirmed reduced numbers of CD11b + cells ( Fig. 6c) and showed that the expression of VEGF and the number of microvessels was reduced after treatment with siCCR2 ( Fig. 6d,e) .
In a second cancer model of colorectal CT26 tumors, we found a 75% reduction of tumor-associated macrophages ( Supplementary  Fig. 10) . Taken together, treatment with siCCR2 reduced the number of tumor-associated macrophages and tumor size; however, future experiments will have to show impact of this therapy at later disease stages and in conjunction with chemotherapy.
Cellular specificity and other gene targets
We were interested to better understand the specificity of siCCR2 treatment and therefore investigated reduction of other leukocytes in cancerous lesions. As expected, we found that silencing of CCR2 primarily reduced the number of inflammatory monocytes, which depend on this receptor for recruitment. Other myeloid cells and lymphocytes were affected less ( Supplementary Fig. 11 ). However, silencing of the pan-leukocyte marker CD45 was also possible in splenic macrophages, Ly-6C low monocytes and dendritic cells ( Supplementary Fig. 12) , implying that the approach is broadly applicable for silencing genes in those cells.
DISCUSSION
The controlled recruitment of monocytes is an essential feature of host defense, but excessive or prolonged recruitment of the inflammatory monocyte subset is harmful, as these cells are mediators of tissue destruction. Here we harnessed RNAi to silence expression of the monocytic chemokine receptor CCR2, which is responsible for the migration of the inflammatory monocyte subset. Migration of monocytes toward MCP-1 is severely attenuated in heterozygous CCR2-deficient mice 28 , making CCR2 an attractive silencing target because even intermediate protein levels translate into impaired migratory capacity of Ly-6C high monocytes.
The motivation for targeting CCR2 in monocytes in this study was based on three major observations: (i) the striking phenotype of CCR2 −/− and MCP-1 −/− mice 1,5-10,29,30 , (ii) prior work linking monocyte subsets to distinct functions in disease and healing 2,3,17,25,31 and (iii) the ease by which monocytes can be targeted by means of their phagocytic activity 32 . Based on recent advances in siRNA formulation designs, we showed by dynamic FMT imaging and flow cytometry that intravenously injected nanoparticles distributed siRNA to immune cells in the blood, bone marrow and spleen, resulting in efficient and specific knockdown of CCR2. Consequently, fewer inflammatory monocytes migrated to the site of inflammation, and disease severity was attenuated in the many models investigated. Because we targeted a recruitment mechanism, sessile immune cells remained largely unaffected.
The effects of siCCR2 treatment on splenic reservoir monocytes proved particularly intriguing. Study of acute myocardial infarction firmly established the dominant role of this emergency reservoir, as more than half of the monocytes recruited to the infarct originate from the spleen 16 . Splenectomy and siCCR2 treatment had no additive effects on recruitment to the infarct, indicating that the splenic monocyte population is a major target of siCCR2 therapy and potentially for any anti-inflammatory strategy focusing on monocytes. The role of splenic monocytes is less well understood in chronic inflammation, and future studies will decipher if lesional foam cells in atherosclerosis and tumor-associated macrophages derive from the splenic monocyte pool. Observed treatment effects in atherosclerosis and cancer in our study likely also result from CCR2 silencing in bone marrow or circulating monocytes.
Our approach is distinct from previous work on gene silencing in leukocytes in several ways. We targeted a monocyte gene that drives recruitment of cells. Interruption of cell migration may be particularly efficient because it removes a cell population from the inflammatory site rather than neutralizing a single gene product. To our knowledge, this is the first demonstration of siRNA delivery to the inflammatory monocyte subset. Silencing CCR2 provides cellular specificity for this emerging therapeutic target. A previous study described silencing after oral administration of yeast-based glucan particles. These micrometer-sized particles were reported as taken up by macrophages in the intestine through a glucan receptor-mediated pathway 11 . A smaller liposome that was comparable in size to the nanoparticle used in our study was formed from phospholipids and featured a monoclonal antibody against integrins as a targeting moiety 12 . The lipidoid nanoparticle preparation used in our study consists of chemically defined entities and comes with important manufacturing advantages 13 , which enhance chances of its clinical use for anti-inflammatory therapy. Structurally related delivery materials have been used successfully for silencing in the liver by independent research groups in several species, with potent knockdown at doses as low as 0.01 mg/kg 33 .
When compared to conventional anti-inflammatory therapy (e.g., steroids, cyclooxygenase-2 inhibitors, methotrexate), silencing CCR2 is set apart by its cellular specificity. Most clinically approved drugs may have molecular specificity but broadly target cells in tissues these compounds distribute to, including cells that should be spared to avoid unwanted side effects. For example, steroids have been tested in individuals with myocardial infarction with disastrous outcomes 34 , and their side effects (fluid retention, diabetes) make them unlikely candidates for treating cardiovascular disease. Other potent immunosuppressive drugs such as methotrexate, used for treatment of rheumatoid arthritis, also lack cellular specificity. Therefore, whereas these drugs suppress inflammation, they also diminish protective functions of the immune system that are involved in the resolution of inflammation, wound healing and defense against infection. In general, delivery of drugs by nanoparticles can increase their concentration at the site of action 35 , which may partially explain the advantage in efficiency when we compared siCCR2 treatment with small-molecule CCR2 inhibitors.
The efficient delivery of siRNA to immune cells provides an avenue to translate the vast knowledge base gained from germline A r t i c l e s inactivation of genes involved in immunity to the clinic. Although we have concentrated on CCR2 in this study, it is logical to extend the approach to other targets in innate immune cells, for instance, proteins involved in proliferation, maturation, differentiation and antigen presentation, such as transcription factors and cytokines. The ability to silence CD45 in other myeloid cells suggests that generalization of the approach is feasible. One particularly appealing aspect of siRNA delivery is the ability to silence multiple targets at the same time. We have shown the efficacy of CCR2 siRNA in cardiovascular disease, cancer and transplant rejection, but other diseases may also respond to such treatment. In sum, this study describes the merging of in vivo RNAi with recent insights into monocyte biology, opening a new translational avenue to approach the many diseases driven by recruitment of these cells.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturebiotechnology/. 
ONLINE METHODS
All experiments were approved by the Subcommittee on Animal Research Care at Massachusetts General Hospital.
Synthesis and in vitro screening of siRNAs.
Thirty-one siRNAs with the lowest predicted off-target potentials and 100% homology with mouse CCR2 gene sequence NM_009915.2 were selected for synthesis and screening. Single-strand RNAs were produced at Alnylam Pharmaceuticals, as previously described, and were annealed and used as duplexes 36 . Mouse macrophage line J774A.1 cells were transfected with siRNA by using Lipofectamine RNAiMAX reagent according to the manufacturer's protocols at 0.1 nM and 10 nM concentrations. CCR2 mRNA levels were quantified 24 h after transfection by quantitative (q)PCR and normalized to GAPDH mRNA. Duplexes showing best knockdown at both concentrations (marked with arrows in Supplementary Fig. 2) were selected for 12-point dose-response ranging from 10 nM down to 0.01 pM to determine IC 50 value for these siRNA duplexes. The best duplex with the sequence of 5′-uGcuAAAc GucucuGcAAAdTsdT-3′ (sense), 5′-UUUGcAGAGACGUUuAGcAdTsdT-3′ (anti-sense) was selected for scaling up, formulating and subsequent in vivo work. Lower case represents 2′-OMe modified residues. For silencing CD45, we used a duplex with the following sequence: 5′-cuGGcuGAAuuucAGA GcAdTsdT-3′ (sense), 5′-UGCUCUGAAAUUcAGCcAGdTsdT-3′ (antisense), as published previously 37 . siRNA formulation into lipid nanoparticles. Nanoparticles were prepared with the cationic lipid C12-200 (ref. 15 ), disteroylphosphatidyl choline, cholesterol and PEG-DMG using a spontaneous vesicle formation procedure. Lipids were dissolved in 90% ethanol solution and mixed with siRNA solution (25 mM citrate, pH 3 ratio) at fixed speed (1:1 ratio) and diluted immediately with PBS to final 25% ethanol. The ethanol was then removed and the external buffer replaced with PBS (155 mM NaCl, 3 mM Na 2 HPO 4 , 1 mM KH 2 PO 4 , pH 7.5) by dialysis. The particles had a component molar ratio of ~50/10/38.5/1.5 (C1 2 -200/disteroylphosphatidyl choline/cholesterol/PEG-DMG). Particle size and zeta potential were determined using a Malvern Zetasizer NanoZS. siRNA content was determined by ion exchange high-performance liquid chromatography (Agilent) assay using DNAPac Pa200 column (Dionex Corporation Dionex, 260 nm, 55 °C run at 2 ml/min). siRNA entrapment efficiency was determined by the Quant-iT RiboGreen RNA assay (Invitrogen) 38 . Briefly, siRNA entrapment was determined by comparing the signal of the RNA-binding dye RiboGreen in formulation samples in the absence and presence of the detergent Triton-X100. In the absence of detergent, signal comes from accessible (unentrapped) siRNA only. In the presence of detergent, signal comes from total siRNA. In all preparations used, the encapsulation was >82%. The polydispersity index of the final formulation was 0.036-0.037.
Dynamic FMT-CT imaging of siRNA biodistribution. FMT-CT imaging was used to evaluate the time-resolved biodistribution of lipid nanoparticle siRNA. This quantitative imaging technique combines noninvasive whole-body fluorescent tomography (determining tissue concentration of AF647-coupled siRNA) with high-resolution CT imaging. To minimize absorbance of photons by fur, nude mice were used for this study, which received a nonfluorescent diet for a week before imaging. After placement of mice into a multimodal imaging cartridge which provides fiducials detected by both modalities for image fusion, contrast-enhanced microCT (Inveon, Siemens) was followed by dynamic FMT imaging on an FMT-2500 system (PerkinElmer). Anesthesia used 1.5% isoflurane (O 2 2 L/min) with a gas delivery system integrated into the multimodal imaging cartridge. After CT imaging, mice were transferred while in the multimodal imaging cartridge and positioned in the FMT scanner with a tail vein in place. Then, a bolus of nanoparticle-encapsulated AF647coupled siRNA was injected at a dose of 1 mg/kg, and mice were imaged every 5 min for 2 h, and then at 4 h, 6 h, 8 h and 24 h after injection. FMT imaging used excitation and emission wavelengths of 635 and 655 nm, respectively. Thirty frontal slices of 0.5 mm thickness in z-direction, with an in-plane resolution of at least 1 × 1 mm were acquired.
Post-processing of FMT data sets was done by using a normalized Born forward equation to calculate fluorochrome concentration expressed in nM fluorescence per voxel. The three-dimensional (3D) data set was reconstructed for the entire mouse. Based on CT information, volumes of interest were defined in respective organs. To co-register FMT and CT images, DICOM-converted data were imported into OsiriX (The OsiriX Foundation). Fiducials on the imaging cartridge were visualized and tagged in FMT and CT images with point markers to define their location in 3D. This allows point-based registration of FMT data to CT coordinates, as described before 39 . Fluorescence measurements in volumes of interest were normalized to weight using average organ weights and expressed as fluorescence per gram tissue.
Disease models. Nude mice were purchased from COX-7 (Massachusetts General Hospital). C57BL/6, BALB/c, CCR2 −/− and apoE −/− (B6.129P2-Apoe tm1Unc ) mice were bought from The Jackson Laboratory. Ischemia reperfusion injury (IRI) was induced, as described previously, by temporary ligation of the left coronary artery 40 . Permanent coronary ligation and splenectomy were done as described before 16 . Diabetes was induced with streptozotocin at 200 mg/kg and was defined as blood glucose levels >300 mg/dl for at least 2 consecutive days. The protocol for islet isolation and transplantation has been described previously 41 . Four to five hundred islets isolated from the major histocompatibility complex-mismatched BALB/c (H-2d) donors were transplanted into renal subcapsular space of diabetic B6 recipients (H-2b). Functional graft was defined as a nonfasting blood glucose level <200 mg/dl and rejection was diagnosed at blood glucose of >200 mg/dl for at least 2 consecutive days. ApoE −/− were 6 months old at the time of analysis and had been kept on a Western diet to induce atherosclerosis (21.2% fat/weight, 0.2% cholesterol; Harlan Teklad) for 4 months. For tumor xenograft models, 10 6 congeneic EL-4 or CT26 tumor cells were injected subcutaneously into the right hind flank of C57BL/6 or BALB/c mice, respectively. Treatment protocols. Mice were treated with a dose of 0.5 mg/kg/day of siCCR2, siLUC (siRNA targeting luciferase as control) or 1 mg/kg/day of fluorochrome-labeled siRNA for biodistribution studies. For the analysis of biodistribution of the drug, mice were treated with a single dose and euthanized after 2 h for flow cytometric analysis and histology. Mice that were used for isolation of splenic monocytes (for quantitative real time PCR, western blot analysis and migration assay) were treated for 3 to 7 d before tissue harvest. Mice undergoing induction of myocardial infarction were pretreated for 3 d before surgery and received treatment on the day of MI. ApoE −/− mice were treated twice a week for 3 weeks before tissue harvest. Islet recipients were treated 3 d before transplantation and then treated twice a week for 4 weeks or until rejection after transplantation. Treatment for mice with tumor cell inoculation was started at the beginning of visible and palpable tumor growth (day 5-10 after implantation) and continued twice a week.
Fluorescence reflectance imaging (FRI). Using a planar fluorescent reflectance imaging system (OV-110, Olympus), tissues were imaged with an excitation wavelength of 630 nm and exposure times of 60-75 msec.
Cell isolation. Mice were euthanized 2 h after injection of fluorochromelabeled siRNA. Peripheral blood was drawn by means of cardiac puncture with citrate solution (100 mM Na-citrate, 130 mM glucose, pH 6.5), as anticoagulant and lysed with RBC Lysis Buffer (BioLegend). Spleens were removed, triturated in HBSS (Mediatech) at 4 °C and filtered through nylon mesh (BD Biosciences) with the end of a 3-ml syringe plunger. The cell suspension was centrifuged at 300g for 10 min at 4 °C. Red blood cells were lysed with ACK lysis buffer, and the splenocytes were washed with HBSS and resuspended in HBSS supplemented with 0.2% (wt/vol) BSA and 1% (wt/vol) FCS. For isolation of bone marrow cells, femurs were flushed with HBSS. For experiments analyzing CCR2 expression including cell sorting, spleens from WT C57BL/6 mice were removed after 7 d of siRNA treatment and processed as described above.
Heart tissue from mice with ischemia reperfusion injury was harvested on day 1 after IRI or permanent coronary ligation. After weighing, tissue was minced with fine scissors, and placed into a cocktail of 450 U/ml collagenase I, 125 U/ml collagenase XI, 60 U/ml DNase I and 60 U/ml hyaluronidase (Sigma-Aldrich) and shaken at 37 °C for 1 h. Cells were then triturated through nylon mesh, centrifuged and resuspended in HBSS supplemented with 0.2% (wt/vol) BSA and 1% (wt/vol) FCS.
Immunofluorescence microscopy of the spleen. Spleens were harvested and embedded in OCT compound (Sakura Finetek) with isopentane on dry ice. Five-micrometer tissue sections were cut, mounted on microscope slides and stored at −80 °C until immunofluorescence staining was done. After brief fixation with 4% paraformaldehyde in PBS, tissue sections were treated with blocking solution (4% rabbit normal serum in PBS), and stained with a biotin-conjugated rat anti-mouse CD11b antibody (clone M1/70; BD Biosciences). As a secondary detection agent Streptavidin-Texas Red (GE Healthcare) was used. Slides were coverslipped using a mounting medium containing DAPI (Vector Laboratories) to identify cell nuclei. Fluorescence microscopy was done at the following wavelengths: UV (D365/10× EX, dichroic 380DCLP BS and emission filter E400LPv2 EM), GFP/FITC (HQ480/40× EX, dichroic Q505LP BS and emission filter HQ535/50 m EM), Y-2E/C (D560/40× EX, dichroic 595DCLP BS and emission filter D630/60m EM). Images were taken using an epifluorescence microscope, Nikon Eclipse 80i (Nikon Instruments), equipped with a Cascade Model 512B camera (Roper Scientific).
Immunohistochemical study. For analysis of treatment effects on the development of atherosclerosis, aortic roots from apoE −/− mice were excised and embedded in OCT compound (Sakura Finetek) on day 21 after the initiation of siRNA treatment. EL4-tumors were removed on day 11 after tumor application and also embedded in OCT. Tissue sections were stained for myeloid cells (CD11b: M1/70, BD Biosciences), endothelial cells (CD31: clone MEC 13.3, BD Biosciences), vascular endothelial growth factor (VEGF, R&D Systems) and macrophages (F4/80: Clone Cl:A3-1, Abcam). The appropriate biotinylated secondary antibody, ABC kit (Vector Laboratories) and AEC substrate (DakoCytomation) were used for color development, and all the sections were counterstained with Harris hematoxylin. For morphological study of islets, H&E staining was done. All the slides were scanned with the NanoZoomer 2.0-RS (Hamamatsu) in ×40 mode, and the positive cell numbers or areas were quantified by cell counting or using IPLab (version 3.9.3; Scanalytics), analyzing five high power fields per section and per animal at magnification of 100× or 200×.
Statistics.
Results are expressed as mean ± s.d. unless stated otherwise. Statistical comparisons between two groups were evaluated by Student's t-test and corrected by ANOVA for multiple comparisons. A value of P < 0.05 was considered to indicate statistical significance. A log-rank test was used to compare pancreatic islet graft survival.
